投资要点公司是一家深耕自免及肿瘤领域的创新药企业,在IL-4Rα、CLDN18.2、CD3等多个领域布局了高潜力管线,其中,核心产品CM310 是国产首家获批的IL-4Rα 抗体药物,已进入商业化阶段。研发中的CLDN18.2 ADC 药物CMG901 临床数据优秀,已进入全球III 期临床。双抗平台中三款CD3 双抗药物多项重磅交易验证了公司创新平台价值。我们看好公司在自免领域领先优势和创新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.